Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share

Summit Therapeutics (NASDAQ: SMMT) reported Q3 EPS of (GBP0.08), versus (GBP0.06) reported last year.

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Summit ivonescimab shows consistent survival data across regions at WCLC
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk